Diamond Sponsors
|
|
|
| Otsuka Pharmaceutical |
|
 |
| |
|
|
|
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases in order to change
the standard of care for patients. Our lead investigational therapy is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A
PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera
Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University
for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal
antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109
and MAU868
|
|
 |
| |
|
|
Platinum Sponsor
|
|
|
| Amgen |
|
 |
| |
|
|
| Bayer's legacy in cardiovascular care spans decades of scientific innovation and patient-focused research. As a long-standing leader in cardiology, Bayer
has consistently advanced therapies that address the complex interplay between the heart and kidneys—two organs deeply connected in both health and disease. Today, that heritage continues to guide our commitment to developing
innovative treatments for patients facing high unmet medical needs. With a growing portfolio of approved therapies and promising compounds in development, Bayer is shaping the future of cardiovascular care through precision
medicine, scientific rigor, and a deep sense of purpose. |
|
 |
| |
|
|
| At Travere Therapeutics we are in rare for life. We come together every day to help patients, families and caregivers as they navigate life
with a rare disease. On this path, we know the need for treatment options is urgent and we work with the rare disease community to identify, develop and deliver life-changing therapies. We continuously seek to understand the
diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. |
|
 |
| |
|
|
Gold Sponsor
|
|
|
| Ardelyx is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant
unmet medical needs. |
|
 |
| |
|
|
Silver Sponsor
|
|
|
| Alnylam Pharmaceuticals |
|
|
| |
|
|
| Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for
some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic
atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. |
|
 |
| |
|
|
|
Mallinckrodt is a leading provider of life-enhancing therapeutics focused on addressing unmet patient needs in the areas of autoimmune and rare diseases, including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. To learn more, visit
www.MNK-Endo.com. |
|
 |
| |
|
|
| Novartis |
|
|
| |
|
|
Bronze Sponsor
|
|
|
| Alexion |
|
|
| |
|
|
| ANI Pharmaceuticals |
|
|
| |
|
|
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January
2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing Aritinercept, a dual inhibitor of B cell
activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Please visit https://www.auriniapharma.com/ to learn more.
|
|
 |
| |
|
|
| Calliditas Therapeutics |
|
|
| |
|
|
| CareDx aspires to achieve its vision — a world where every patient receives the transplant they need to live longer, fuller lives. We are driven by our mission
to create life-changing solutions that enable transplant patients to thrive. |
|
 |
| |
|
|
| Central Florida Kidney Centers (CFKC) is an independent, non-profit dialysis organization dedicated to delivering compassionate care to the kidney community for over
53 years. We provide a full range of services—including in-center dialysis, peritoneal dialysis, and home hemodialysis—for both adult and pediatric patients. Guided by our commitment to quality and personalized care, CFKC proudly
lives by the motto: “Large enough to serve. Small enough to care. |
|
 |
| |
|
|
| At CorMedix Therapeutics, we’re driven to protect vulnerable patients from serious, life-threatening infections. With eight commercial-stage products spanning
prevention and treatment, we address critical, unmet needs across multiple care settings. Our dedicated team is committed to ensuring access to our therapies and to continuously expanding our portfolio to improve patient outcomes. |
|
 |
| |
|
|
| Eurofins Transplant Genomics Meeting the needs of transplant patients and providers is a challenge
unlike another. From pre- to post-transplant, we’re equipped with testing solutions that can do just that. Eurofins Transplant Genomics and Eurofins Ascend come together to provide testing solutions for all stages of the transplant
journey. |
|
 |
| |
|
|
Fresenius Medical Care North America We Help Make Dialysis Care Happen.
When you partner with Fresenius Medical Care (FME), you get 30-plus
years of renal therapies expertise. You get a product portfolio that covers nearly every aspect of dialysis care and many of the most recognized product names in the industry. You get exceptional customer service and a truly
reliable supply chain. In short, you get what you need when you need it, so your patients can too.
|
|
 |
| |
|
|
| Genentech pioneered the biotech industry, combining rigorous science with cutting-edge technology in a way never seen before – and that same spirit of disrupting
the status quo and setting new standards continues to fuel us as we pursue the medicines of tomorrow. |
|
 |
| |
|
|
| MedPro |
|
|
| |
|
|
DNA is in our blood
Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make
personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.
|
|
 |
| |
|
|
| Novo Nordisk |
|
|
| |
|
|
| OPKO Renal |
|
|
| |
|
|
| Practice Pays |
|
|
| |
|
|
| Risk Strategies |
|
|
| |
|
|
| |
|
|
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Florida Women in Nephrology Chair
FSN President
Print Page